Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1 | Q15116 | 19/20 | 0.47 |
| ▸ | CD274 | Q9NZQ7 | 19/20 | 0.47 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20293099 | 1.00 | PDCD1 (0.47) | PDCD1CD274USP30 | |
| SCHEMBL29593538 | 0.92 | PDCD1 (0.49) | PDCD1CD274 | |
| SCHEMBL20293441 | 0.92 | PDCD1 (0.49) | PDCD1CD274 | |
| SCHEMBL30033637 | 0.89 | PDCD1 (0.50) | PDCD1CD274USP30 | |
| Potassium Ion SCHEMBL29831283 | 0.89 | PDCD1 (0.46) | PDCD1CD274 | |
| SCHEMBL30661752 | 0.86 | PDCD1 (0.37) | PDCD1CD274USP30 | |
| SCHEMBL30661738 | 0.86 | PDCD1 (0.43) | PDCD1CD274USP30 | |
| SCHEMBL23685522 | 0.86 | PDCD1 (0.63) | PDCD1CD274 | |
| SCHEMBL30661758 | 0.84 | PDCD1 (0.36) | PDCD1CD274USP30 | |
| SCHEMBL30145362 | 0.83 | PDCD1 (0.53) | PDCD1CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577260-B2 | Biphenyl compound as immunomodulator, preparation method therefor and application thereof | SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD. (CN) | 2026-03-17 | — | — | US | disclosed |
| US-12473282-B2 | Biphenyl fluorine double bond derivative, preparation method therefor, and pharmaceutical application thereof | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2025-11-18 | — | — | US | disclosed |
| EP-4520328-A2 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | Incyte Corporation (US) | 2025-03-12 | — | — | EP | disclosed |
| US-20240109919-A1 | BIPHENYL COMPOUND AS IMMUNOMODULATOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD. (CN) | 2024-04-04 | — | — | US | disclosed |
| US-20230014651-A1 | BIPHENYL FLUORINE DOUBLE BOND DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL APPLICATION THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2023-01-19 | — | — | US | disclosed |
| EP-3558990-B1 | TETRAHYDRO IMIDAZO[4,5-C]PYRIDINE DERIVATIVES AS PD-L1 INTERNALIZATION INDUCERS | INCYTE CORP (US) | 2022-08-10 | — | — | EP | disclosed |
| EP-3558963-B1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORP (US) | 2022-03-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12473282-B2 | Biphenyl fluorine double bond derivative, preparation method therefor, and pharmaceutical application thereof | PDCD1, CD274, PDCD1LG2 | PDCD1 1/4885CD274 2/4885USP30 3962/4885 |
| US-20230014651-A1 | BIPHENYL FLUORINE DOUBLE BOND DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL APPLICATION THEREOF | PDCD1, CD274, PDCD1LG2 | PDCD1 1/4885CD274 2/4885USP30 3962/4885 |
| US-12577260-B2 | Biphenyl compound as immunomodulator, preparation method therefor and application thereof | CCR1, CCR6, CCL11 | PDCD1 533/4885CD274 114/4885USP30 4416/4885 |
| US-20240109919-A1 | BIPHENYL COMPOUND AS IMMUNOMODULATOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | ICOS, ICOSLG, CD40LG | PDCD1 100/4885CD274 18/4885USP30 2961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.